share_log

Bristol Myers Squibb Provides Update On First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia For Crohn's Disease; Study Did Not Meet Its Primary Endpoint Of Clinical Remission At Week 12

Bristol Myers Squibb Provides Update On First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia For Crohn's Disease; Study Did Not Meet Its Primary Endpoint Of Clinical Remission At Week 12

Bristol Myers Squibb提供了評估口服Zeposia治療克羅恩氏病的第三期黃石試驗的最新情況；該研究在第12周未達到臨床緩解的主要終點
Benzinga ·  03/29 04:02

The safety profile of Zeposia in this study was consistent with that observed in previously reported trials. The company will complete a full evaluation of the YELLOWSTONE trial data and work with investigators to share the results with the scientific community in the future.

的安全概況 澤波西亞 這項研究與先前報告的試驗中觀察到的結果一致。該公司將完成對YELLOWSTONE試驗數據的全面評估，並與研究人員合作，在未來與科學界分享結果。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論